Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (365)	2/3/1999 9:22:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 613

Henry, looks like Incyte came in with a nickle when 0.20 was expected...yet I see this in the PR The net income for the quarter and year ended December 31, 1998 were impacted by the ramp up in expenses related to the genomic sequencing and single nucleotide polymorphism (SNP) discovery programs previously attributed to the Incyte Genetics business unit. Excluding the impact of this business unit, net income would have been $6.9 million or diluted earnings per share of $0.23 for the quarter ended December 31, 1998. So what do you make of all that--if it dips a bit more early today perhaps a buying op? Do you follow incy, I'd ask Rocketman, but I saw you were online etc...